Sia Biotec is a spin-off company from the ETH Zurich pioneering a novel half-life extension technology. We are at the forefront of in vivo glycoprotein engineering. Our proprietary platform enables the targeted protein modification with a biodegradable sugar polymer, streamlining the development of next-generation therapeutics